← Patent-cliff monitor Loss of exclusivity September 2032 latest FDA-listed patent expiry
Company TAKEDA PHARMACEUTICALS USA INC
Drug detail Brand name TRINTELLIX Active ingredient VORTIOXETINE HYDROBROMIDE Strength EQ 5MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval September 2013 Marketing status RX
Listed patents Patent Expires Type 9278096*PED September 2032 — 9278096 March 2032 use U-2436 8722684*PED December 2031 — 8722684 June 2031 substance, product 11458134*PED December 2027 — 8969355*PED December 2027 — 9227946*PED December 2027 — 9125908*PED December 2027 — 9125909*PED December 2027 — 9125910*PED December 2027 — 9861630*PED December 2027 — 9125908 June 2027 use U-2309 9861630 June 2027 use U-1668 9227946 June 2027 use U-1668 11458134 June 2027 product 9125909 June 2027 use U-2309 8969355 June 2027 use U-1668 9125910 June 2027 use U-2309 7144884*PED December 2026 — 7144884 June 2026 substance, product
Regulatory exclusivity Code Expires PED February 2027 M-232 August 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.